The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Synthetic ZFTA fusions pinpoint disordered protein domain acquisition as a mechanism of brain tumorigenesis
Open accessPublished version of a preprint
Abstract
Over 95% of ependymomas that arise in the cortex are driven by a gene fusion involving the zinc finger translocation-associated (ZFTA) protein. Here, using super-resolution and lattice light-sheet microscopy, we demonstrate that the most frequent fusion variant, ZFTA–RELA (ZR), forms dynamic nuclear condensates that are required for oncogene expression and tumorigenesis. Mutagenesis studies of ZR reveal a key intrinsically disordered region (IDR) in RELA that governs condensate formation. Condensate-modulating IDR mutations introduced into ZR impaired its genomic occupancy at oncogenic loci and inhibited the recruitment of transcriptional effector proteins, such as MED1, BRD4 and RNA polymerase II. Using nuclear magnetic resonance spectroscopy, we examined the DNA-binding residues of the critical zinc finger (ZF1) found in ZR and characterized their significance for condensate formation, genomic binding and oncogene activation. We generated synthetic ZFTA fusion proteins where IDRs from known condensate-forming proteins were grafted into ZR. Synthetic ZFTA fusion oncoproteins utilizing IDRs from EWS and FUS restored condensate formation, oncogene transcription and tumour initiation in mice. These findings provide key insights into the oncogenic mechanism of ZR and the importance of IDR acquisition in fusion oncoproteins in brain cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Highly accurate protein structure prediction with AlphaFold
Jumper, J., Evans, R., Pritzel, A., Green, T., Figurnov, M., Ronneberger, O., Tunyasuvunakool, K., Bates, R., Žídek, A., Potapenko, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03819-2 · Cited by 43,764
Flagged first, then by citations
Research works printed but not linked: 48
- Pajtler, K. W. et al. The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants. Acta Neuropathol. 133, 5–12 (2017). · DOI
- Hwang, E. I., Hanson, D., Filbin, M. G. & Mack, S. C. Why haven’t we solved intracranial pediatric ependymoma? Current questions and barriers to treatment advances. Neoplasia 39, 100895 (2023). · DOI
- Saleh, A. H. et al. The biology of ependymomas and emerging novel therapies. Nat. Rev. Cancer 22, 208–222 (2022). · DOI
- Arabzade, A. et al. ZFTA–RELA dictates oncogenic transcriptional programs to drive aggressive supratentorial ependymoma. Cancer Discov. 11, 2200–2215 (2021). · DOI
- Kupp, R. et al. ZFTA translocations constitute ependymoma chromatin remodeling and transcription factors. Cancer Discov. 11, 2216–2229 (2021). · DOI
- Ozawa, T. et al. A de novo mouse model of C11orf95–RELA fusion-driven ependymoma identifies driver functions in addition to NF-κB. Cell Rep. 23, 3787–3797 (2018). · DOI
- Zheng, T. et al. Cross-species genomics reveals oncogenic dependencies in ZFTA/C11orf95 fusion-positive supratentorial ependymomas. Cancer Discov. 11, 2230–2247 (2021). · DOI
- Parker, M. et al. C11orf95–RELA fusions drive oncogenic NF-κB signalling in ependymoma. Nature 506, 451–455 (2014). · DOI
- Herranz-Pérez, V. et al. Ependymoma associated protein Zfta is expressed in immature ependymal cells but is not essential for ependymal development in mice. Sci. Rep. 12, 1493 (2022). · DOI
- Mitrea, D. M. & Kriwacki, R. W. Phase separation in biology; functional organization of a higher order. Cell Commun. Signal 14, 1 (2016). · DOI
- Banani, S. F., Lee, H. O., Hyman, A. A. & Rosen, M. K. Biomolecular condensates: organizers of cellular biochemistry. Nat. Rev. Mol. Cell Biol. 18, 285–298 (2017). · DOI
- Ahn, J. H. et al. Phase separation drives aberrant chromatin looping and cancer development. Nature 595, 591–595 (2021). · DOI
- Chandra, B. et al. Phase separation mediates NUP98 fusion oncoprotein leukemic transformation. Cancer Discov. https://doi.org/10.1158/2159-8290.CD-21-0674 (2021). · DOI
- Boulay, G. et al. Cancer-specific retargeting of BAF complexes by a prion-like domain. Cell 171, 163–178 (2017). · DOI
- Terlecki-Zaniewicz, S. et al. Biomolecular condensation of NUP98 fusion proteins drives leukemogenic gene expression. Nat. Struct. Mol. Biol. 28, 190–201 (2021). · DOI
- Qin, Z. et al. Phase separation of EML4–ALK in firing downstream signaling and promoting lung tumorigenesis. Cell Discov. 7, 33 (2021). · DOI
- Shirnekhi, H. K., Chandra, B. & Kriwacki, R. The role of phase-separated condensates in fusion oncoprotein–driven cancers. Annu. Rev. Cancer Biol. 7, 73–91 (2023). · DOI
- Zuo, L. et al. Loci-specific phase separation of FET fusion oncoproteins promotes gene transcription. Nat. Commun. 12, 1491 (2021). · DOI
- Chong, S. et al. Imaging dynamic and selective low-complexity domain interactions that control gene transcription. Science https://doi.org/10.1126/science.aar2555 (2018). · DOI · Paper page
- Feric, M. et al. Coexisting liquid phases underlie nucleolar subcompartments. Cell 165, 1686–1697 (2016). · DOI
- Mack, S. C. et al. Therapeutic targeting of ependymoma as informed by oncogenic enhancer profiling. Nature 553, 101–105 (2018). · DOI
- Tripathi, S. et al. Defining the condensate landscape of fusion oncoproteins. Nat. Commun. https://doi.org/10.1038/s41467-023-41655-2 (2023). · DOI
- Chen, H. C. et al. Histone serotonylation regulates ependymoma tumorigenesis. Nature 632, 903–910 (2024). · DOI
- Chen, F. E., Huang, D. B., Chen, Y. Q. & Ghosh, G. Crystal structure of p50/p65 heterodimer of transcription factor NF-κB bound to DNA. Nature 391, 410–413 (1998). · DOI
- Bhimsaria, D. et al. Specificity landscapes unmask submaximal binding site preferences of transcription factors. Proc. Natl Acad. Sci. USA 115, E10586–e10595 (2018). · DOI
- Lee, M. S., Gippert, G. P., Soman, K. V., Case, D. A. & Wright, P. E. Three-dimensional solution structure of a single zinc finger DNA-binding domain. Science 245, 635–637 (1989). · DOI
- Hu, X. et al. Nuclear condensates of YAP fusion proteins alter transcription to drive ependymoma tumourigenesis. Nat. Cell Biol. 25, 323–336 (2023).
- Wang, Y. et al. Dissolution of oncofusion transcription factor condensates for cancer therapy. Nat. Chem. Biol. 19, 1223–1234 (2023). · DOI
- Cai, D. et al. Phase separation of YAP reorganizes genome topology for long-term YAP target gene expression. Nat. Cell Biol. 21, 1578–1589 (2019). · DOI
- Klein, I. A. et al. Partitioning of cancer therapeutics in nuclear condensates. Science 368, 1386–1392 (2020). · DOI
- Kilgore, H. R. et al. Distinct chemical environments in biomolecular condensates. Nat. Chem. Biol. https://doi.org/10.1038/s41589-023-01432-0 (2023). · DOI
- Ambadi Thody, S. et al. Small-molecule properties define partitioning into biomolecular condensates. Nat. Chem. 16, 1794–1802 (2024). · DOI
- Kilgore, H. R. et al. Distinct chemical environments in biomolecular condensates. Nat. Chem. Biol. 20, 291–301 (2024). · DOI
- Riggi, N. et al. EWS-FLI1 utilizes divergent chromatin remodeling mechanisms to directly activate or repress enhancer elements in Ewing sarcoma. Cancer Cell 26, 668–681 (2014). · DOI
- Wei, M. T. et al. Nucleated transcriptional condensates amplify gene expression. Nat. Cell Biol. 22, 1187–1196 (2020). · DOI
- Liu, G. et al. Characterization, comparison, and optimization of lattice light sheets. Sci. Adv. 9, eade6623 (2023). · DOI
- Shi, Y., Daugird, T. A. & Legant, W. R. A quantitative analysis of various patterns applied in lattice light sheet microscopy. Nat. Commun. 13, 4607 (2022). · DOI
- Ahrens, J., Geveci, B. & Law, C. in Visualization Handbook (eds Hansen C. D. & Johnson C. R.) 717–731 (Butterworth-Heinemann, 2005). · DOI
- Schindelin, J. et al. Fiji: an open-source platform for biological-image analysis. Nat. Methods 9, 676–682 (2012). · DOI · Paper page
- Kay, L. E., Xu, G. Y. & Yamazaki, T. Enhanced-sensitivity triple-resonance spectroscopy with minimal H2O saturation. J. Magn. Reson. A 109, 129–133 (1994). · DOI
- Muhandiram, D. R. & Kay, L. E. Gradient-enhanced triple-resonance three-dimensional NMR experiments with improved sensitivity. J. Magn. Reson. B 103, 203–216 (1994). · DOI
- Grzesiek, S. & Bax, A. Amino acid type determination in the sequential assignment procedure of uniformly 13C/15N-enriched proteins. J. Biomol. NMR 3, 185–204 (1993). · DOI
- Delaglio, F. et al. NMRPipe: a multidimensional spectral processing system based on UNIX pipes. J. Biomol. NMR 6, 277–293 (1995). · DOI
- Lee, W., Tonelli, M. & Markley, J. L. NMRFAM-SPARKY: enhanced software for biomolecular NMR spectroscopy. Bioinformatics 31, 1325–1327 (2015). · DOI
- Lee, W. et al. I-PINE web server: an integrative probabilistic NMR assignment system for proteins. J. Biomol. NMR 73, 213–222 (2019). · DOI
- Hafsa, N. E., Arndt, D. & Wishart, D. S. CSI 3.0: a web server for identifying secondary and super-secondary structure in proteins using NMR chemical shifts. Nucleic Acids Res. 43, W370–W377 (2015). · DOI
- Heinig, M. & Frishman, D. STRIDE: a web server for secondary structure assignment from known atomic coordinates of proteins. Nucleic Acids Res. 32, W500–W502 (2004). · DOI · Paper page
- Scholz, J., Besir, H., Strasser, C. & Suppmann, S. A new method to customize protein expression vectors for fast, efficient and background free parallel cloning. BMC Biotechnol. 13, 12 (2013). · DOI
Metadata
- Authors
- Arabzade, A., Shirnekhi, H. K., Varadharajan, S., Ippagunta, S. M., Phillips, A. H., Laboe, N., Baggett, D. W., Wahiduzzaman, Jo, M., Zheng, T., Pathak, R., Gee, D., Bhimsaria, D., Wu, H., Gao, X., Liu, J., Emanus, E., Bland, A., Kardian, A., Hancock, A., Holcomb, B., Wright, T., Bugbee, T., Sun, H., Zhai, M., Caesar, E., Park, M., Tripathi, S., Shirinifard, A., Lowe, K., Khalighifar, A., Petersen, R. A., King, S., Stabley, D., Pitre, A., Campbell, G. E., Park, C.-G., Freyaldenhoven, W. T., Chandra, B., Xia, Y., Bonten, E., Achari, A., Kandikonda, S., Carisey, A., Pounds, S. B., Xu, J., Ellison, D. W., Deneen, B., Bertrand, K. C., Kriwacki, R. W., & Mack, S. C.
- Affiliations
- St. Jude Children's Research Hospital (US)
- Indian Institute of Technology Roorkee (IN)
- Baylor College of Medicine (US)
- Corresponding author
- Kriwacki, R. W.
- Mack, S. C.
- ORCID
- Arabzade, A.
- Shirnekhi, H. K.
- Varadharajan, S.
- Ippagunta, S. M.
- Laboe, N.
- Baggett, D. W.
- Jo, M.
- Zheng, T.
- Bhimsaria, D.
- Wu, H.
- Liu, J.
- Emanus, E.
- Kardian, A.
- Holcomb, B.
- Bugbee, T.
- Sun, H.
- Zhai, M.
- Shirinifard, A.
- Khalighifar, A.
- Petersen, R. A.
- Stabley, D.
- Pitre, A.
- Campbell, G. E.
- Chandra, B.
- Xia, Y.
- Carisey, A.
- Pounds, S. B.
- Xu, J.
- Ellison, D. W.
- Deneen, B.
- Bertrand, K. C.
- Kriwacki, R. W.
- Mack, S. C.
- Venue
- Nature Cell Biology
- Published
- 2025-08-27
- Volume
- 27
- Issue
- 9
- Pages
- 1496-1509
- ISSN
- 1465-7392 (ISSN-L)
- 1476-4679
- PMC
- PMC12431856
- OpenAlex
- W4413740186
- Cited by
- 7
- References
- 1
- Citations by year
- 2026: 7
- FWCI
- 2.10
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Nature Cell Biology (publishedVersion, cc-by)
- Research Square (acceptedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- Funders
- U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30 CA021765, R01CA284455, R01CA280203, U01CA281823, U01CA294103, R01CA246125, U54CA243124)
- Alex's Lemonade Stand Foundation for Childhood Cancer (A Award (Mack))
- U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (R01NS128184)
- U.S. Department of Defense (CA220510, CA220247)
- National Brain Tumor Society ((Mack))
- American Lebanese Syrian Associated Charities ((Mack))
- CERN Foundation, Robert Connor Dawes Foundation
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- ependymoma, intrinsically disordered regions, nuclear condensates, fusion oncoproteins, brain tumorigenesis, RelA, DNA-binding residues, oncogene activation, MED1, BRD4, RNA polymerase II
- MeSH terms
- Protein Domains, Animals, Brain Neoplasms, Humans, Transcription Factors, Oncogene Proteins, Fusion, Gene Expression Regulation, Neoplastic, Zinc Fingers, RNA-Binding Protein FUS, RNA-Binding Protein EWS, Cell Line, Tumor, Mice, Transcription Factor RelA, Carcinogenesis, Intrinsically Disordered Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review